Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Current Assets for 10 consecutive years, with $951.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 16.4% to $951.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $951.0 million through Dec 2025, up 16.4% year-over-year, with the annual reading at $951.0 million for FY2025, 16.4% up from the prior year.
  • Current Assets for Q4 2025 was $951.0 million at Ultragenyx Pharmaceutical, up from $643.2 million in the prior quarter.
  • The five-year high for Current Assets was $1.1 billion in Q1 2021, with the low at $596.0 million in Q1 2024.
  • Average Current Assets over 5 years is $799.8 million, with a median of $783.0 million recorded in 2023.
  • The sharpest move saw Current Assets tumbled 40.83% in 2023, then surged 37.39% in 2024.
  • Over 5 years, Current Assets stood at $856.6 million in 2021, then increased by 3.19% to $883.9 million in 2022, then dropped by 17.16% to $732.2 million in 2023, then grew by 11.58% to $817.0 million in 2024, then rose by 16.4% to $951.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $951.0 million, $643.2 million, and $719.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.